Consensus Alkermes plc

Stocks

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-21 EDT			5-day change	1st Jan Change
48.33 ^USD	+0.65%		-1.49%	+72.73%

08-12	Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities	CI
08-04	Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing	MT

Evolution of the Average Target: Alkermes plc

Evolution of the Target Price: Alkermes plc

Changes in Analyst Recommendations: Alkermes plc

1e72c74a90cf6b28dd055574735cee0.HtQhBIazrAD9QemkK25STnl9tbhJ-BI7QsNWwpth9Tk.WZ9PM_zDymWHMNv2cVwIAxUP8Y0IzVZTdoE7-90uowt7knNuwIbEabY3sA~b7f5e40d4749d8e5de930781db6cb708

Analysts' recommendations: Alkermes plc

07-29	Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says	MT
06-29	Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says	MT
06-29	BofA Securities Downgrades Alkermes to Underperform From Neutral, $38 Price Target	MT
06-22	Deutsche Bank Lifts Alkermes Price Target to $60 From $47, Maintains Buy Rating	MT
06-09	Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says	MT
06-09	RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating	MT
05-06	Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says	MT
05-06	UBS Adjusts Price Target on Alkermes Public to $48 From $42, Maintains Buy Rating	MT
04-09	BofA Adjusts Price Target on Alkermes Public to $36 From $34, Maintains Neutral Rating	MT
04-07	RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating	MT
02-26	RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating	MT
02-18	Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating	MT
11-19	Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says	MT
11-17	Truist Raises Price Target on Alkermes to $55 From $50, Keeps Buy Rating	MT
11-13	Deutsche Bank Lowers Price Target on Alkermes to $45 From $55, Keeps Buy Rating	MT
11-11	Truist Initiates Alkermes at Buy With $50 Price Target	MT
25-10-29	Deutsche Bank Adjusts Alkermes Price Target to $55 From $53, Maintains Buy Rating	MT
25-10-23	RBC Raises Price Target on Alkermes to $47 From $45, Keeps Outperform Rating	MT
25-10-08	RBC Lifts Price Target on Alkermes to $45 From $44, Keeps Outperform Rating	MT
25-09-26	Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says	MT
25-09-26	RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42	MT
25-09-03	Wells Fargo Initiates Alkermes Public at Overweight With $44 Price Target	MT
25-07-30	RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating	MT
25-06-17	UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33	MT
25-05-28	Needham Initiates Alkermes Public at Buy With $45 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALKERMES PLC					+16.62%
	LONZA GROUP AG					+16.27%
	REVOLUTION MEDICINES, INC.					+5.43%
	IQVIA HOLDINGS INC.					+7.47%
	BEONE MEDICINES AG					+17.3%
	CELLTRION, INC.					+37.06%
	MEDPACE HOLDINGS, INC.					-5.03%
	ASCENDIS PHARMA A/S					+22.78%
	EUROFINS SCIENTIFIC SE					-0.4%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.59%
	Average					+11.39%
	Weighted average by Cap.					+12.96%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

48.33USD

Average target price

56.00USD

Spread / Average Target

+15.87%

High Price Target

72.00USD

Spread / Highest target

+48.98%

Low Price Target

38.00USD

Spread / Lowest Target

-21.37%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Deutsche Bank Securities
RBC Capital Markets
UBS
Truist Securities
Wells Fargo Securities
Needham & Co.
Stifel Nicolaus
TD Cowen
Cantor Fitzgerald
Baird
Piper Sandler
Evercore ISI
Mizuho Securities
HC Wainwright
JPMorgan Chase
SVB Leerink
Goldman Sachs
Citigroup